Thermo Fisher Scientific Inc.
TMO
NYSE·Healthcare·Medical - Diagnostics & Research·Mkt cap $228.1B
$613.78
▼ -0.75%
P/E
33.02
Mkt Cap
$228.1B
52-Wk Range
$435.27–$647.00
52-Week Range
$435.27 - $647.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Comprehensive integrated platform spanning life sciences, diagnostics, and analytical instruments with unmatched breadth
- Strong brand portfolio including Thermo Scientific, Applied Biosystems, Invitrogen, and Fisher Scientific with deep customer loyalty
- Extensive global distribution network and direct sales force providing superior customer access and support
- Significant R&D investment and proprietary technology portfolio creating sustainable competitive moats
- Strategic acquisitions and scale enabling cost advantages and cross-selling opportunities across customer base
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Increasing global demand for biopharmaceutical development and personalized medicine solutions
Value
Attractively priced below Life Sciences Tools peer average
Momentum
Hot
+30.7% over 3m
Quality
Strong
Excellent business quality
Dividend
Token
0.29% yield
Smart-money signal
Who's buying TMO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 23, 2026
Reported EPS of $6.03 vs $5.72 consensus (+5.4% surprise). Revenue of $12.0B vs $11.7B expected (+2.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+5.4%
Revenue trend · last 8Q
—
+5%
+0%
+3%
+5%
+7%
+6%
+10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$10.6B
$11.4B
$10.4B
$10.9B
$11.1B
$12.2B
$11.0B
$12.0B
Margins · last 8Q
Gross
41.2%
Operating
17.4%
Profit
14.5%
Wall Street consensus
11 analysts · 73% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
73%
Hold
27%
Sell
0%
Median Price Target
—
Latest: CLSA · Sep 3, 2026
vs Industry
How TMO stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related